Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Treating HER2+ Metastatic Breast Cancer

February 22nd 2017

Extended Adjuvant Therapy for HER2+ Early Breast Cancer

February 22nd 2017

HER2-Targeted Therapy in Early Stage HER2+ Breast Cancer

February 22nd 2017

PI3K Inhibitors in HR+ Metastatic Breast Cancer

February 22nd 2017

Everolimus for HR+ Metastatic Breast Cancer

February 22nd 2017

Emerging Role of Abemaciclib for HR+ Advanced Breast Cancer

February 22nd 2017

Ribociclib for HR+ Advanced Breast Cancer

February 22nd 2017

FALCON Trial Data in HR+ Metastatic Breast Cancer

February 22nd 2017

Breast Cancer: Extended Adjuvant Endocrine Therapy

February 22nd 2017

Comparison of Prognostic Tests in Breast Cancer

February 22nd 2017

Breast Cancer: Genomic Testing

February 22nd 2017

MINDACT Trial Design and Results in Breast Cancer

February 22nd 2017

Breast Cancer: Genomic Testing for Adjuvant Therapy

February 22nd 2017

Dr. White on CNS Metastases in HER2+ Breast Cancer

February 22nd 2017

Julia White, MD, The Ohio State University Comprehensive Cancer Center, discusses brain metastases in patients with HER2-positive breast cancer.

Dr. Kalinsky on Optical Imaging for HER2+ Breast Cancer

February 21st 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.

Olaparib Improves PFS in Phase III BRCA+ Breast Cancer Trial

February 17th 2017

The PARP inhibitor olaparib improved progression-free survival versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.

Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer

February 14th 2017

Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

Breast Density Surpasses Other Risk Factors in Development of Breast Cancer

February 9th 2017

High breast density surpasses other known risk factors for developing breast cancer, including family history of the disease, personal history of benign lesions, and later-in-life childbirth, according to the results of a study published in JAMA Oncology.

Dr. Tjan-Heijnen on Results of DATA Study in Breast Cancer

February 9th 2017

Vivianne Tjan-Heijnen, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, discusses the results of the phase III DATA study.

Dr. White On RTOG 1119 Trial for Breast Cancer

February 9th 2017

Julia White, MD, professor of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, discusses RTOG-1119 trial for patients with breast cancer.